Novartis eyes chief executive shake-up in 2018

September 4, 2017

Swiss pharmaceutical giant Novartis said Monday its chief executive for the past seven years, Joseph Jimenez, will step down in 2018, allowing chief medical officer Vasant Narasimhan to take the reins.

Jimenez, who joined Novartis in 2007 and took over as CEO in 2010, had informed the board of directors of his wish to relinquish his leadership position early next year, Novartis said in a statement.

He will step down on January 31, but has agreed to remain available to provide advice and support until he retires from Novartis on August 31, it added.

"Both from a professional and a personal perspective, this is the right moment to hand the leadership reins of the company to Vas," Jimenez said in the statement, pointing to the company's "strong pipeline" and insisting Novartis was "on a strong path for the future."

"On the personal side, after 10 wonderful years in Switzerland, my family is ready to return to Silicon Valley and the US," he said, adding: "I'm confident that Vas will be an excellent successor."

Narasimhan, who will take over as on February 1, joined Novartis in 2005.

The US citizen, who is 41, holds a medical degree and a public policy degree from Harvard, and previously worked for McKinsey & Company.

The married father of two is currently serving as the global head of drug development and chief medical officer at Novartis.

"We anticipate a smooth transition," Joerg Reinhardt, chairman of the Novartis board said in the statement.

Explore further: Novartis to buy back $5 bn in shares

Related Stories

Novartis to buy back $5 bn in shares

January 25, 2017
Swiss pharmaceutical giant Novartis announced Wednesday a $5.0 billion share buyback even though competition from generics ate away at sales and earnings last year.

Novartis Korea executives charged for bribing doctors

August 13, 2016
Prosecutors have indicted the former chief executive of the South Korean unit of Novartis and five other former and current managers over allegations they illegally paid doctors 2.6 billion won ($2.3 million) in return for ...

Roche 'extremely open' to talks with Novartis: report

October 1, 2013
The head of Swiss pharmaceutical giant Roche is open to renewed cooperation with competitor Novartis, he told the Financial Times in an interview published Tuesday.

Novartis chief sees sales dip until mid-2013

October 7, 2012
Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.

Novartis Q4 net profit rebounds to $2.1 billion

January 23, 2013
(AP)—Swiss drug maker Novartis AG reported a jump in fourth-quarter net profit to $2.08 billion on Wednesday, citing the lack of a $900-million one-time charge it took in the same period the previous year.

Novartis to use Google technology for eye care

July 15, 2014
Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease.

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.